CDD-2807

CDD-2807 is a highly potent and selective small-molecule inhibitor of serine/threonine kinase 33 (STK33), developed as a non-hormonal, reversible male contraceptive. It was discovered through DNA-encoded library screening and subsequent medicinal chemistry optimization by researchers at Baylor College of Medicine, with contributions from Promega Corporation. CDD-2807 inhibits STK33 at low nanomolar concentrations (IC50 ~9.2 nM) and demonstrates over ninefold selectivity versus other kinases. In preclinical studies in mice, the compound efficiently crosses the blood-testis barrier without accumulating in the brain or causing systemic toxicity. Treatment with CDD-2807 reduces sperm motility and alters sperm morphology, leading to temporary infertility; these effects are fully reversible upon discontinuation of treatment. The drug does not affect testis size or overall health in animal models, making it a promising candidate for further development as an oral male contraceptive[3][4][5][6][8].